The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
946
April 14, 1995
View Complete Issue         Table of Contents 2019 
Nefazodone for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nefazodone for Depression
April 14, 1995 (Issue: 946)
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nefazodone for Depression
Article code: 946a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.